STOCK TITAN

Hemostemix Inc - HMTXF STOCK NEWS

Welcome to our dedicated news page for Hemostemix (Ticker: HMTXF), a resource for investors and traders seeking the latest updates and insights on Hemostemix.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Hemostemix's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Hemostemix's position in the market.

Rhea-AI Summary
Hemostemix Inc. announces positive Phase II clinical trial results for ACP-01 in treating critical limb ischemia. The trial showed a significant decrease in ulcer size, lower amputation and mortality rates compared to the placebo group. The 1-year death rate in the ACP-01 treatment group was substantially lower than the literature's reported rates. The company plans to produce ACP-01 for revenue and conduct further clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.47%
Tags
clinical trial
-
Rhea-AI Summary
Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) closed a private placement of $320,385 with the issuance of 2,669,875 units. The Corporation paid eligible finders aggregate fees of $5,750.40 in cash and issued 47,920 finder options to purchase common shares. The Board of Directors authorized the issuance of 2,375,000 Stock Options at $0.07 each to Directors, Officers, and Consultants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Hemostemix Inc. has announced the publication of its seventh peer-reviewed study on ACP-01 as a treatment for heart disease. The study demonstrates that ACP-01 can regenerate and improve cardiac function in patients with ischemic and non-ischemic dilated cardiomyopathy. The results show an increase in cardiac function of up to 24.1% at 12 months in ischemic cardiomyopathy patients and up to 47.1% at 12 months in non-ischemic cardiomyopathy patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Hemostemix Inc. announces amendment to $2.5 million convertible debenture, resulting in expected interest saving of $569,868.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.78%
Tags
none
-
Rhea-AI Summary
Hemostemix Inc. closed a private placement of $320,125, selling approximately 2.66 Million Units at $0.12 each. Proceeds will be used for production of ACP-01, filing fees, and working capital.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.02%
Tags
none
-
News
Rhea-AI Summary
Hemostemix Inc. announces a new private placement of $325,125, selling approximately 2.7 million units at $0.12 each. Proceeds will be used for production, filing fees, and working capital. Directors may participate in the placement. Additional funds were not received for a second tranche closing. The private placement is subject to regulatory approvals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Hemostemix Inc. announces study of NCP-01 supporting brain computer interfaces submitted for peer review publication.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.6%
Tags
none
-
Rhea-AI Summary
Hemostemix Inc. incorporates Hemostemix Quebec Inc. and applies for $6 Million grant funding to locate production of ACP-01 in Montreal. Negotiated terms for a possible shared site to reduce costs. Drafted phase II heart clinical trial protocol. Plans to build out production and generate revenue from the sale of ACP-01.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.56%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.76%
Tags
clinical trial
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.6%
Tags
none
Hemostemix Inc

OTC:HMTXF

HMTXF Rankings

HMTXF Stock Data

5.29M
74.06M
11.95%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
Canada
Calgary